Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.

Cancer letters - 10 Apr 2015

Schechter Rebecca B, Nagilla Madhavi, Joseph Loren, Reddy Poluru, Khattri Arun, Watson Sydeaka, Locati Laura D, Licitra Lisa, Greco Angela, Pelosi Giuseppe, Carcangiu Maria Luisa, Lingen Mark W, Seiwert Tanguy Y, Cohen Ezra E W

Abstract excerpt

Biomarkers predicting which patients with advanced radioiodine-resistant differentiated thyroid cancer (DTC) may benefit from multi-kinase inhibitors are unavailable. We aimed to describe molecular markers in DTC that correlate with clinical outcome to axitinib. Pretreatment thyroid cancer blocks from 18 patients treated with axitinib were collected and genomic DNA was isolated. The OncoCarta™ Mutation Panel was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Screening Assays, Antitumor
Share to Indazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Iodine Radioisotopes

Share to Radiation Tolerance

Share to Radiopharmaceuticals

Share to Vascular Endothelial Growth Factor Receptor-1

Share to Vascular Endothelial Growth Factor Receptor-2

Share to Vascular Endothelial Growth Factor Receptor-3

Source

Identifiers

PMID: 25641339
DOI: 10.1016/j.canlet.2015.01.024

Genes

KRAS
BRAF
HRAS
MET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.PMID 25641339Read ↗

Targeted therapy in thyroid cancer: molecular alterations and clinical management.Semantic proximity Read ↗

Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?: A multicenter experience.Semantic proximity Read ↗

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.Semantic proximity Read ↗

Evolving molecularly targeted therapies for advanced-stage thyroid cancers.Semantic proximity Read ↗

New Therapies for Advanced Thyroid Cancer.Semantic proximity Read ↗

Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.Semantic proximity Read ↗

Oncogenic mutations in the TP53 and PI-3 kinase/AKT pathway are independent predictors of survival for advanced thyroid cancer: Analysis from the Molecular Screening and Therapeutics (MoST) program.Semantic proximity Read ↗

Histology-based molecular profiling improves mutation detection for advanced thyroid cancer.Semantic proximity Read ↗

Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy.Semantic proximity Read ↗

Clinical relevance of gene mutations and rearrangements in advanced differentiated thyroid cancer.Semantic proximity Read ↗

Molecular Profile of Advanced Radioiodine-refractory Thyroid Cancer and Response to Lenvatinib Treatment.Semantic proximity Read ↗

Next-Generation Sequencing in Differentiated Thyroid Cancer Patients Treated with Lenvatinib: Results and Challenges in Real-Life Practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.